
Why Pfizer and BioNTech Are Beating Moderna in the Omicron Booster Market
Moderna is still prevailing in the omicron booster market in at least one important way.
Moderna is still prevailing in the omicron booster market in at least one important way.
There's more than one factor driving recent outperformance of these shares.
Less debt and a smaller dividend payment let's AT&T focus on growth opportunities.
These reliable businesses are posting impressive results.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.